0
Nov 16 (Reuters) – Johnson & Johnson said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies. The drugmaker
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)